Bridging pharmacodynamic biomarkers to clinical outcomes in pediatric inflammatory diseases
将药效生物标志物与儿科炎症性疾病的临床结果联系起来
基本信息
- 批准号:9753019
- 负责人:
- 金额:$ 82.42万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-19 至 2021-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdultAffinityAgeAgonistAnti-inflammatoryAppearanceAsthmaBiologicalBiological MarkersChemistryChildChildhoodChronicClinicalClinical TrialsCushingoid habitusCytoprotectionDataDevelopmentDiseaseDoseDrug IndustryDrug PrescriptionsDrug effect disorderDuchenne muscular dystrophyFamilyFundingGlucocorticoid ReceptorGlucocorticoidsGoalsGovernmentGrowthHealth systemHistologicImageInflammationInflammatoryInflammatory Bowel DiseasesLabelLongitudinal StudiesMedicineMembraneMineralocorticoid ReceptorModificationMonitorMoodsNational Institute of Child Health and Human DevelopmentOutcomeOutcome MeasurePatientsPharmaceutical PreparationsPharmacodynamicsPilot ProjectsPopulationPre-Clinical ModelPrednisonePremature BirthPropertyProteinsQuality of lifeRare DiseasesResearchResearch PersonnelResearch Project GrantsResearch SupportSafetySeriesSerumSleep disturbancesSteroidsTestingTherapeuticTrainingTraining SupportTransactivationValidationVertebral columnVisionbiomarker discoverybiomarker panelbone fragilitycare costsclinical carecostdesigndrug developmentexperienceimprovedinnovationinterestlung developmentnegative affectnext generationnovelpediatric drug developmentpediatric patientspediatric pharmacologypediatricianpharmacodynamic biomarkerprogramsside effectstandard of care
项目摘要
Abstract:
Daily administration of high dose glucocorticoids is standard of care for the treatment of many
pediatric inflammatory diseases, including Duchenne Muscular Dystrophy (DMD) and Inflammatory
Bowel Disease (IBD). The side effect profiles of these potent drugs in children can be severe, with
stunting of growth, bone fragility, mood changes, and sleep disturbances among many others. It is
rare for glucocorticoids to be approved and labeled for pediatric disorders where they are routinely
being prescribed, despite these serious side effect profiles. Glucocorticoids were first approved for
use in adult disorders in the 1950s, yet progress on discovery and development of the next
generation drugs with significantly improved side effect profiles has been surprisingly slow. This has
been attributed to the complexity of mechanisms of actions of glucocorticoids (both with regards to
safety and efficacy), the growth in use of biologics for many pediatric diseases, and the lack of
interest from the pharmaceutical industry given the pervasive use and low cost of traditional
glucocorticoids. However, particularly in children, the decrease in quality of life and the increase in
clinical care ‘costs’ caused by side effects of glucocorticoids are substantial, but have been poorly
studied. This U54 RPDP application is from an established group with expertise in pediatric
pharmacology (inclusive of a newly funded NICHD T32 in clinical pediatric pharmacology), pediatric
drug development, and chronic inflammatory diseases in children. In this application, we focus on
pediatric inflammatory disorders, using two disease exemplars, DMD and IBD, as these may prove to
be great representatives of chronic pediatric diseases treated with glucocorticoids. The team at the
Children’s National Health System (CNHS) has partnered with an innovative venture philanthropy
company, ReveraGen BioPharma, to bridge pharmacodynamic biomarkers to clinical outcomes in the
pediatric population. In preliminary data presented in longitudinal studies of both IBD and DMD, we
describe validated panels of pharmacodynamic biomarkers for both multiple aspects of safety, as
well as anti-inflammatory efficacy. These pharmacodynamic safety and efficacy biomarkers are being
used to evaluate a promising next generation anti-inflammatory steroid (VBP15/vamorolone). The
goals of the proposed projects in this application are to bridge pharmacodynamic biomarkers to
clinical outcomes for specific safety and efficacy aspects of both glucocorticoids (prednisone) and
VBP15. This will set the stage for clinical trials of vamolorone and other anti-inflammatory drugs in
pediatric inflammatory diseases, where the data obtained is expected to enable more acute and
objective readouts of drug action in pediatric patients using well-characterized pharmacodynamic
biomarkers as outcome measures.
摘要:
每日给予高剂量糖皮质激素是治疗许多糖尿病的标准护理。
小儿炎症性疾病,包括杜氏肌营养不良症(DMD)和炎性
肠道疾病(IBD)。这些强效药物在儿童中的副作用可能很严重,
生长发育迟缓、骨骼脆弱、情绪变化和睡眠障碍等。是
糖皮质激素很少被批准和标记用于儿科疾病,
尽管有这些严重的副作用糖皮质激素首次被批准用于
20世纪50年代在成人疾病中使用,但在发现和开发下一个
具有显著改善的副作用特征的药物的产生令人惊讶地缓慢。这
这归因于糖皮质激素作用机制的复杂性(关于
安全性和有效性),许多儿科疾病使用生物制剂的增长,以及缺乏
由于传统的药物的普遍使用和低成本,
糖皮质激素然而,特别是在儿童中,生活质量的下降和
由糖皮质激素副作用引起的临床护理“成本”是巨大的,但一直很差,
研究了该U 54 RPDP应用程序来自一个具有儿科专业知识的成熟小组
药理学(包括临床儿科药理学新资助的NICHD T32),儿科
药物开发和儿童慢性炎性疾病。在本应用程序中,我们重点关注
儿科炎症性疾病,使用两种疾病范例,DMD和IBD,因为这些可能证明,
是糖皮质激素治疗慢性儿科疾病的伟大代表。的研究小组
儿童国家卫生系统(CNHS)与一家创新的风险慈善机构合作,
ReveraGen BioPharma公司,将药效学生物标志物与临床结果联系起来,
儿科人群。在IBD和DMD纵向研究的初步数据中,我们
描述了经验证的药效学生物标志物组的多个安全性方面,
以及抗炎功效。这些药效学安全性和有效性生物标志物正在
用于评估有前途的下一代抗炎类固醇(VBP 15/vamorolone)。的
本申请中提出的项目的目标是将药效学生物标志物与
糖皮质激素(泼尼松)和
VBP15。这将为瓦莫罗龙和其他抗炎药物的临床试验奠定基础,
儿科炎症性疾病,其中获得的数据有望使更多的急性和
使用充分表征的药效学在儿科患者中客观读出药物作用
生物标志物作为结果测量。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHANNES NICOLAAS VAN DEN ANKER其他文献
JOHANNES NICOLAAS VAN DEN ANKER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHANNES NICOLAAS VAN DEN ANKER', 18)}}的其他基金
Bridging pharmacodynamic biomarkers to clinical outcomes in pediatric inflammatory diseases
将药效生物标志物与儿科炎症性疾病的临床结果联系起来
- 批准号:
9229110 - 财政年份:2016
- 资助金额:
$ 82.42万 - 项目类别:
Bridging pharmacodynamic biomarkers to clinical outcomes in pediatric inflammatory diseases
将药效生物标志物与儿科炎症性疾病的临床结果联系起来
- 批准号:
9354195 - 财政年份:2016
- 资助金额:
$ 82.42万 - 项目类别:
Postdoctoral training in Pediatric Clinical Pharmacology
儿科临床药理学博士后培训
- 批准号:
9113782 - 财政年份:2016
- 资助金额:
$ 82.42万 - 项目类别:
Pediatric toxicity and efficacy in long-term systemic treatment with anti-sense
反义药物长期全身治疗的儿科毒性和疗效
- 批准号:
8338884 - 财政年份:2011
- 资助金额:
$ 82.42万 - 项目类别:
Pediatric toxicity and efficacy in long-term systemic treatment with anti-sense
反义药物长期全身治疗的儿科毒性和疗效
- 批准号:
8246746 - 财政年份:2011
- 资助金额:
$ 82.42万 - 项目类别:
Pediatric toxicity and efficacy in long-term systemic treatment with anti-sense
反义药物长期全身治疗的儿科毒性和疗效
- 批准号:
8677920 - 财政年份:2011
- 资助金额:
$ 82.42万 - 项目类别:
Pediatric toxicity and efficacy in long-term systemic treatment with anti-sense
反义药物长期全身治疗的儿科毒性和疗效
- 批准号:
8472511 - 财政年份:2011
- 资助金额:
$ 82.42万 - 项目类别:
Pediatric toxicity and efficacy in long-term systemic treatment with anti-sense
反义药物长期全身治疗的儿科毒性和疗效
- 批准号:
8883644 - 财政年份:2011
- 资助金额:
$ 82.42万 - 项目类别:
MULTIPLE DOSE PHARMACOKINETIC STUDY OF MEROPENEM IN YOUNG INFANTS (91 DAYS)
美罗培南多剂量小婴儿药代动力学研究(91天)
- 批准号:
8167326 - 财政年份:2010
- 资助金额:
$ 82.42万 - 项目类别:
Metabolism and Toxicity of Acetaminophen in Preterm Infants
对乙酰氨基酚在早产儿中的代谢和毒性
- 批准号:
7849339 - 财政年份:2010
- 资助金额:
$ 82.42万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 82.42万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 82.42万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 82.42万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 82.42万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 82.42万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 82.42万 - 项目类别:
Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
- 批准号:
2230829 - 财政年份:2023
- 资助金额:
$ 82.42万 - 项目类别:
Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 82.42万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 82.42万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 82.42万 - 项目类别:
Grant-in-Aid for Scientific Research (C)